# GlycosBio Food Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glycosbio-food-sciences

- Industry: Food
- Headquarters: Houston, US
- Website: www.glycosbio.com
- Total disclosed funding: $17M
- Latest round: Series B (Feb 27, 2013)
- Investors on record: 5

## About

GlycosBio Food Sciences, Inc. specializes in advanced lipid technologies that enhance the therapeutic performance of natural bioactive molecules for healthcare applications.Founded in 2007, GlycosBio Food Sciences, Inc. operates out of Houston, US, focusing on developing innovative lipid technologies. The founder, Daniel Monticello, has a background in biotechnology, and the company has engaged in 7 deals to date. The most recent funding round was a VENTURE DEBT raising of USD 0.40 mn in February 2014 from DFJ Mercury, bringing the total amount raised to USD 3.00 mn.GlycosBio specializes in developing advanced lipid technologies designed to enhance the therapeutic performance of natural bioactive molecules. Their primary offerings include Activated Oil Systems that leverage enzymology and lipid engineering techniques to address various health conditions, particularly in patients with gastrointestinal complications such as exocrine pancreatic insufficiency (EPI). The products aim to influence microbiota across different bodily systems, including intestinal, pulmonary, and skin microbiota, serving as alternative therapies for dysbiosis and reducing reliance on antibiotics. GlycosBio collaborates with clients across North America and Europe, targeting healthcare providers and pharmaceutical companies focused on enhancing patient outcomes through innovative therapeutic products.GlycosBio generates revenue through strategic partnerships and collaborations in the healthcare and pharmaceutical sectors, focusing on research and development services along with product licensing. The company sponsors in vitro and in vivo clinical trials to validate its technologies, which lead to revenue through IP licensing agreements, allowing clients to manufacture and sell products using GlycosBio’s proprietary technologies. The revenue model involves B2B arrangements where clients pay for access to GlycosBio’s patented solutions, facilitating the development of advanced therapeutic products.GlycosBio plans to continue innovating new products in lipid technologies, with several products under design targeted for launch in the upcoming years. The company is planning to expand its presence specifically in the European market by 2025. The recent VENTURE DEBT funding of USD 0.40 mn will be utilized to support these product developments and market expansion initiatives.

## Funding rounds

- Series B, Feb 27, 2013, $3M — Draper Fisher Jurvetson
- Series B, Oct 6, 2010, $6.8M — Draper Fisher Jurvetson, Mercury, The Gideon Hixon Fund, DNX Ventures, EIV Capital
- Series A, Apr 17, 2009, $5M — Draper Fisher Jurvetson, Mercury
- Series A, Feb 1, 2008, $2.4M — Draper Fisher Jurvetson, Mercury

## Investors

- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series A, Series B
- Mercury (https://capitalatlas.ai/funds/mercury) — Series A, Series B
- The Gideon Hixon Fund (https://capitalatlas.ai/funds/the-gideon-hixon-fund) — Series B
- DNX Ventures (https://capitalatlas.ai/funds/dnx-ventures) — Series B
- EIV Capital (https://capitalatlas.ai/funds/eiv-capital) — Series B